Unexpected consequences of proton pump inhibitor use

Otolaryngology - Head and Neck Surgery

Volumn 141, Issue 5, 2009, Pages 564-566

  Altman, Kenneth W ^a   Radosevich, James A ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PANTOPRAZOLE; PEPSIN A; PROTON PUMP INHIBITOR;

ACIDITY; ALPHA CHAIN; ARTICLE; ATROPHIC GASTRITIS; BACTERIAL INFECTION; BETA CHAIN; COMMUNITY ACQUIRED PNEUMONIA; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DRUG ABSORPTION; GASTROESOPHAGEAL REFLUX; HIP FRACTURE; HUMAN; IMMUNOHISTOCHEMISTRY; IRON DEFICIENCY; LARYNGOPHARYNGEAL REFLUX; LARYNX MUCOSA; LIVER METABOLISM; MICROENVIRONMENT; PATHOGENESIS; SIDE EFFECT;

GASTROESOPHAGEAL REFLUX; HUMANS; HYPOPHARYNX; PEPSIN A; PROTON PUMP INHIBITORS;

EID: 70350489787     PISSN: 01945998     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otohns.2009.08.027     Document Type: Article

References (15)

1. Altman K.W., Stephens R.M., Lyttle C.S., et al. Changing impact of gastroesophageal reflux in medical and otolaryngology practice. Laryngoscope 115 (2005) 1145-1153
2. Samuels T.L., and Johnston N. Pepsin as a causal agent of inflammation during nonacid reflux. Otolaryngol Head Neck Surg 141 (2009) 559-563
3. Johnston N., Bulmer D., Gill G.A., et al. Cell biology of laryngeal epithelial defenses in health and disease: further studies. Ann Otol Rhinol Laryngol 112 (2003) 481-491
4. Johnston N., Knight J., Dettmar P.W., et al. Pepsin and carbonic anhydrase isoenzyme III as diagnostic markers for laryngopharyngeal reflux disease. Laryngoscope 114 (2004) 2129-2134
5. Samuels T.L., Handler E., Syring M.L., et al. Mucin gene expression in human laryngeal epithelia: effect of laryngopharyngeal reflux. Ann Otol Rhinol Laryngol 117 (2008) 688-695
6. Altman K.W., Waltonen J.D., Hammer N.D., et al. Proton pump expression in human laryngeal seromucinous glands. Otolaryngol Head Neck Surg 133 (2005) 718-724
7. +-ATPase proton pump. Ann Otol Rhinol Laryngol 116 (2007) 229-234
8. Yang Y.X., Lewis J.D., Epstein S., et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296 (2006) 2947-2953
9. McColl K.E. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 104 2 Suppl (2009) S5-S9
10. Aseeri M., Schroeder T., Kramer J., et al. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 103 (2008) 2308-2313
11. Laheij R.J., Sturkenboom M.C., Hassing R.J., et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292 (2004) 1955-1960
12. Siller-Matula J.M., Spiel A.O., Lang I.M., et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157 (2009) 148 e1-5
13. Raghunath A.S., O'Morain C., and McLoughlin R.C. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 22 Suppl 1 (2005) 55-63
14. Altman K.W., Chhaya V., Hammer N.D., et al. Effect of proton pump inhibitor pantoprazole on growth and morphology of oral Lactobacillus strains. Laryngoscope 118 (2008) 599-604
15. Vesper B.J., Jawdi A., Altman K.W., et al. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab 10 (2009) 84-89